Abstract
Thyroid hormones (THs) have a salutary metabolic effect but exert negative effects on the cardiovascular system and other extrahepatic tissues when used in euthyroid individuals. For targeting metabolic diseases, TH analogs with thyroid receptor β selectivity and increased hepatic exposure have been designed. Several of these agents have shown possibility of benefit in nonalcoholic fatty liver disease and dyslipidemia with resmetirom being the most promising of the lot. In addition, the hepatomitogenic and neurotrophic role of thyromimetics is also promising. This narrative review looks back at the evidence that exists with these agents and also looks at their probable role in future.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
